Aclarion, Inc. announced that its Board of Directors unanimously adopted a limited duration stockholder rights plan effective immediately and expiring on March 18, 2027. The plan, commonly known as a "poison pill," is intended to enable all stockholders to realize the long-term value of their investment in the company and reduce the likelihood of any entity gaining control without paying all stockholders an appropriate control premium.
The Rights Plan applies equally to all current and future stockholders and was not adopted in response to any specific acquisition proposal. According to the company, the plan is not intended to deter offers or preclude the Board from considering offers that are fair and otherwise in the best interests of all stockholders. Instead, it aims to ensure the Board has sufficient time to make informed decisions that benefit Aclarion and its shareholders.
Under the terms of the Rights Plan, Aclarion declared a dividend distribution of one preferred stock purchase right for each share of common stock and each Rights-Eligible Warrant outstanding as of March 30, 2026. These rights will initially trade with and be represented by the common stock and warrants. Each right entitles the holder to purchase one one-thousandth of a share of Series D Junior Participating Preferred Stock at a cash exercise price of $14.00 per right, subject to adjustment.
The rights become exercisable if any entity, person, or group acquires beneficial ownership of 10% or more of the common stock in a transaction not approved by the Board. Existing owners with 10% or more ownership prior to the announcement are grandfathered but cannot increase their ownership without triggering the plan. For more detailed information about the Rights Plan, investors can refer to the current report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.
If triggered, each right would entitle its holder to receive shares of common stock having a market value equal to twice the exercise price of the right. In a merger or similar change of control, rights holders would receive shares of the acquiring company's common stock with equivalent value. The Board retains the option to exchange each right for one share of common stock or redeem the rights at $0.001 per right. The plan does not contain any dead-hand, slow-hand, or no-hand provisions that would limit a future Board's ability to redeem the rights.
This corporate governance move has significant implications for investors and the broader healthcare technology sector. For shareholders, the plan provides protection against potential undervalued acquisitions while allowing the Board to evaluate legitimate offers thoroughly. The one-year duration indicates this is a temporary defensive measure rather than a permanent structural change. For the industry, such rights plans can influence acquisition strategies and valuation approaches for publicly traded healthcare technology companies.
Aclarion, which trades on Nasdaq under symbols ACON and ACONW, is a healthcare technology company focusing on chronic low back pain treatment through its Nociscan platform. The company's adoption of this Rights Plan comes as it continues to develop its proprietary Magnetic Resonance Spectroscopy technology and augmented intelligence algorithms. Additional company information is available at https://www.aclarion.com.
The implementation of stockholder rights plans typically signals management's belief in the company's future growth potential and desire to protect shareholder interests during development phases. While such plans can deter hostile takeovers, they also ensure that any acquisition proposals receive proper evaluation to maximize shareholder value. The limited duration aspect provides flexibility while addressing current corporate governance considerations.
